MedPath

Timing of Direct Current Cardioversion (DCC) in Patients Undergoing Ablation of Persistent/Permanent Atrial Fibrillation

Not Applicable
Completed
Conditions
Atrial Fibrillation
Interventions
Procedure: DCC first then PVI
Procedure: PVI then DCC after
Registration Number
NCT02429648
Lead Sponsor
The Cleveland Clinic
Brief Summary

The purpose of this study is to compare which strategy is superior in patients with persistent/permanent atrial fibrillation (AF) undergoing ablation, direct current cardioversion (DCC) prior to empirical pulmonary vein isolation (PVI) ; or pulmonary vein isolation (PVI)ablation in atrial fibrillation then Direct current cardioversion (DCC) if the patient remains in atrial fibrillation.

Detailed Description

Ablation of persistent/permanent Atrial Fibrillation (AF) remains a challenge. There are several strategies to improve the outcomes of persistent/permanent AF ablation. At the Cleveland Clinic one of the commonly used strategies is Direct Current Cardioversion (DCC). Depending on physician preference, patients may be ablated in atrial fibrillation then Direct current cardioverted; or Direct current cardioverted and ablated in sinus rhythm. Neither approach has been shown to be superior. As both approaches are currently being performed based on physician preference, the investigators propose to study and compare both approaches in a randomized fashion for evidence based practice.

The purpose of this study is to compare which standard of care strategy is superior in patients with persistent/permanent Atrial Fibrillation undergoing ablation, direct current cardioversion prior to empirical pulmonary vein isolation; or ablation in atrial fibrillation then direct current cardioversion if the patient remains in atrial fibrillation

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Persistent or long standing persistent AF resistant to anti-arrhythmic medication. Must have been present for more than 2 months
  • Therapeutic anticoagulation for at least three weeks prior to initiation of therapy, or TEE performed prior to the procedure
  • Age >= 18 years old. (Females must be either post-menopausal >12 months, practicing a protocol-acceptable method of birth control
  • Scheduled for Pulmonary Vein Isolation
  • Amiodarone will be stopped at least 3 months prior to procedure
Exclusion Criteria
  • Reversible causes of AF such as pericarditis, hyperthyroidism
  • Presently with Valvular Heart disease requiring surgical intervention
  • Presently with coronary artery disease requiring surgical intervention
  • Early Post-operative AF (within three months of surgery)
  • Previous MAZE or left atrial instrumentation
  • Life expectancy <= 2 years
  • Social factors that would preclude follow up or make compliance difficult.
  • Contraindication to the use of anti-arrhythmic medications and/or coumadin and heparin
  • Enrollment in another investigational drug or device study
  • Patients with severe pulmonary disease
  • Documented intra-atrial thrombus, tumor, or another abnormality which precludes catheter introduction

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PVI performed in Normal Sinus RhythmDCC first then PVIDCC first then PVI
PVI performed in Atrial FibrillationPVI then DCC afterPVI then DCC after if patient remains in Atrial Fibrillation
Primary Outcome Measures
NameTimeMethod
Duration of procedureday of procedure
Secondary Outcome Measures
NameTimeMethod
Composite of duration of fluoroscopy, and radiation exposure dosesday of procedure
Composite of AT/AF burden and total frequency measured by event monitor, holter and/or EKG12 months
frequency of symptomatic atrial arrhythmias measured by event monitor, holter, and/or EKG12 months

Trial Locations

Locations (1)

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath